natgillin/translations-raw huggingface dataset:
A targeted therapeutic fusion protein comprising an amino acid sequence at least 85% identical to a human a-N-acetylglucosaminidase (Naglu) protein, a peptide tag having an amino acid sequence at least 70% identical to amino acids 8-67 of mature human IGF-II and a spacer peptide located between the Naglu amino acid sequence and the IGF-II peptide tag, wherein the spacer comprises the amino acid sequence GAP (SEQ ID NO: 9), GPS (SEQ ID NO: 10), or GGS (SEQ ID NO: 11). 
Ciljani terapeutski fuzijski protein koji sadrži sekvencu aminokiseline koja je barem 85% identična ljudskom o-Nacetilglukozaminidaza proteinu (Naglu), peptidnu oznaku koja ima sekvencu aminokiseline koja je barem 70% identična aminokiselinama 8-67 od zrelog ljudskog IGF-II i razdvajajući peptid smješten između sekvence aminokiseline Naglu i peptidne oznake IGF-IL, naznačen time da razmaknica sadrži sekvencu aminokiseline GGGGS (SEQ ID NO: 12) ili GGGPS (SEQ ID NO: 14).
The anti-TSLP human antibody of claim 1, comprising: a light chain variable domain sequence selected from the group consisting of: 
2. -Anti-TSLP ljudsko protutijelo iz patentnog zahtjeva 1, sadrži: a. varijabilnu domenu lakog lanca izabranu iz grupe koja sadrži: i.
digital/analog conversion of the locked universal reference signal. 
- < digitalno/analogno pretvaranje spomenutog zaključanog univerzalnog referentnog signala.
However, the low intensity sweetener may also have a sweetness that is about equal to that of sucrose or is at least in same order of magnitude as that of sucrose. 
No i sladilo male slatkoće može posjedovati slatkoću jednaku slatkoći saharoze, ili je ona u najmanju ruku jednakog reda veličine kao 1 slatkoća saharoze.
The pellet fraction having an unsuitable particle size is transferred back to the pelletization process after grinding. 
Frakcija granula koje su neodgovarajuće veličine vraća se nakon mljevenja natrag u proces granuliranja.
This resin is specially designed for the purification of antibodies (Boschetti et al. 2000 and Life Technologies Inc. 
Ova je smola dizajnirana specifično u svrhu hvatanja imunoglobulina (Boschetti 2000 i Lifc technologies Inc.
The pharmaceutical combination for use according to any of the preceding claims, wherein the basal insulin is selected from insulin glargine, insulin detemir, isophane insulin, lente insulin, ultralente insulin, and mixtures thereof. 
Farmaceutska kombinacija za uporabu prema bilo kojem od prethodnih zahtjeva, naznačena time da je bazalni inzulin odabran iz niza koji sadrži inzulin glargin, detemir inzulin, izofan inzulin, lente inzulin, ultralente inzulin, te njihove smjese.
According to one aspect of the present invention, the water and water soluble organics after the second filtering step may be transformed into drinkable water in a process of reverse osmosis. 
Metoda u skladu s patentnim zahtjevom 15, pri čemu su voda i u vodi topive organske tvari nakon drugog koraka filtriranja transformirani u pitku vodu u postupku reverzne osmoze.
Bottle 20 would be filled with a mixture of water and inoculant according to a priori knowledge or recommended instructions for a given application rate, crop and/or inoculant. 
Boce 20 će se napuniti mješavinom vode i inokulanda prema nekom prethodnom saznanju ili preporučenim instrukcijama za danu brzinu nanošenja, usjev i/ili inokulant.
The crude product was re-crystallized from EtOH. 
Kruti produkt se rekristalizira iz EtOH.
The present invention also relates to the use of ciclesonide, a pharmaceutically acceptable salt, solvates or physiologically functional derivative thereof for the manufacture of a medicament for the treatment or prevention of a respiratory disease in a patient, which patient is a child and wherein the medicament is administered at a dose of 20 to 200 ug ciclesonide. 
Uporaba ciklesonida, njegove farmaceutski prihvatljive soli, njegovih solvata ili njegovih fiziološki učinkovitih derivata, naznačena time, da je za proizvodnju lijeka za liječenje ili prevenciju bolesti dišnih puteva kod pacijenta, dok pacijent je dijete, pri čemu se smanjuje ili izbjegava pojačanje zagušenja koje je popratna pojava povezana s inhaliranim i intranazalno unesenim kortikosteroidima, te pri čemu se lijek primjenjuje u dozi od 20 do 200 ug ciklesonida.
The method of claim 1, wherein the 40 mg dose of glatiramer acetate is in a prefilled syringe for self administration by the patient. The method of claim 1, wherein the patient has not received glatiramer acetate therapy prior to initiation of the regimen. 
Glatiramer acetat u obliku farmaceutskog sastava za uporabu prema bilo kojem od patentnih zahtjeva 1 ili 2, naznačen time, da čovjek kao pacijent nije primio terapiju glatiramer acetatom prije početka liječenja.
separating hydrogen from the gaseous mixture in the gas chromatography column (22); 
- < izdvajanje vodika iz smjese plinova u koloni za plinsku hromatografiju (22);
Use according to any of the preceding items, wherein the formulation comprises from about 0.02% to 100% w/w such as, e.g. from about 0.1% to about 95% w/w, from about 1% to about 95% w/w, from about 5% to about 95% w/w, from about 10% to about 90% w/w, from about 15% to about 90% w/w of the one or more oligomers of lactic acid. 
Jedan ili više oligomera mliječne kiseline za uporabu prema bilo kojem prethodnom patentnom zahtjevu, pri čemu je jedan ili više oligomera mliječne kiseline sadržan u pripravku koji sadrži od 0.02% do 100% w/w, od 0.1% do 95% w/w, od 1% do 96% w/w, od 5% do 95% w/w, od 10% do 90% w/w, od 15% do 90% w/w jednog ili više oligomera mliječne kiseline.
The connection means may be a liquid electrolytic medium, in which case a membrane which allows electrons to pass through, and possibly some ions, but not atoms, may be provided. 
Uređaj kako je zatraženo u zahtjevu 10, naznačen time da spojna sredstva sadrže membranu koja omogućava da elektroni prolaze kroz nju, te vjerojatno nešto iona, ali ne i atomi.
A pharmaceutical composition comprising the compound according to any one of clauses 1 to 21, the amorphous Form C of clause 22 or 23, or the crystalline Form B of any one of clauses 24 to 28, and a pharmaceutically acceptable carrier, adjuvant, or vehicle. 
Farmaceutski pripravak naznačen time što sadrži spoj ili sol prema bilo kojem od patentnih zahtjeva od 1 do 4i od 6 do 8, amorfni oblik prema patentnom zahtjevu 9 ili kristalni Oblik B prema patentnom zahtjevu 10 i farmaceutski prihvatljiv nosač, adjuvant ili medij.
A combination according to claim 18 wherein the co-agent is selected from inotropes, beta adrenergic receptor blockers, HMG-Co-A reductase inhibitors, angiotensin II receptor antagonists, angiotensin converting enzyme (ACE) Inhibitors, calcium channel blockers (CCB), endothelin antagonists, renin inhibitors, diuretics, ApoA-I mimics, antidiabetic agents, obesity-reducing agents, aldosterone receptor blockers, endothelin receptor blockers, aldosterone synthase inhibitors (ASI), a CETP inhibitor, anticoagulants, relaxin, BNP (nesiritide) and/or a NEP inhibitor. 
Kombinacija prema zahtjevu 18, naznačena time, da je ko-agens odabran od sljedećih: inotropni spojevi, beta blokatori adrenergijskih receptora, inhibitori reduktaze HMG-Co-A, antagonisti receptora angiotenzina II, inhibitori enzima pretvorbe angiotenzina (ACE), blokatori kanala kalcija (CCB), antagonisti endotelina, inhibitori renina, diuretici, ApoA-I-mimetici, antidijabetska sredstva, sredstva za smanjenje pretilosti, blokatori receptora aldosterona, blokatori receptora endotelina, inhibitori sinteze aldosterona (ASI), CEPT-inhibitor, antikoagulanti, relaksin, BNP (nesiritid) i/ili NEP-inhibitor.
urologic disorders selected from overactive bladder, benign prostatic hyperplasia, and erectile dysfunction; neurological disorders selected from Alzheimer's disease, Parkinson's disease and neuropathic pain; and renal disease and diabetes; 
HR P20191755 T1 neurološki poremećaji odabrani od Alzheimerove bolesti, Parkinsonove bolesti i neuropatskih bolova; i bubrežne bolesti i dijabetes; pri čemu postupak obuhvaća primjenu terapeutski učinkovite količine spoja pacijentu kojemu je to potrebno.
The compound of claim 1, wherein R2 is -C1-4alkyl-RA. 
Spoj prema zahtjevu 1, pri čemu R2 je -CH2-RA .
A method for controlling undesired plants or inhibiting their growth, which comprises applying a herbicidally effective amount of from 1 to 200 g/ha of (A) as defined in Claim 1 and a herbicidally effective amount of from 100 to 5,000 g/ha of (B) as defined in Claim 1 to the undesired plants or to a place where they grow. 
Postupak za kontroliranje neželjenih biljaka ili sprječavanje njihovog rasta, naznačen time, da sadrži primjenu herbicidno učinkovite količine od 1 do 200 g/ha od (A) kako je definirano u patentnom zahtjevu 1 i herbicidno učinkovite količine od 100 do 500 g/ha od (B) kako je definirano u patentnom zahtjevu 1 na neželjene biljke ili na mjesta na kojima rastu. t>&
The monoclonal antibody or antigen binding fragment thereof of claim 1, which binds to at least four CC chemokines selected from the group consisting of CCL3/MIP-1a, CCL4/MIP-1B, CCL5/RANTES, and CCL23/MPIF-1, and which does not bind to CCL2/MCP-1. 
Monoklonsko protutijelo, ili njegov fragment koji veže antigen, u skladu s patentnim zahtjevom 1, naznačeno time, da veže na najmanje četiri CC kemokina odabranih 1z skupine koja se sastoji od CCL3/MIP-1a, CCLA/MIP-1$f, CCLS/RANTES, i CCL23/MPIF-1, i koji se ne vežu na CCL2/MCP-I1.
A flexible suspension device, which may be adjusted according to need, is thus provided. 
Na taj se način daje fleksibilna ovjesna naprava koja se može prilagoditi u skladu s potrebom.
and R5 together with the carbon to which they are attached form a cycloalkyl ring; 
Rui Rs zajedno s ugljikom na kojega su priključeni, tvore cikloalkilni prsten;
In another aspect, the present invention includes compounds of formula IV: 
Spoj prema zahtjevu 1, pri čemu navedeni spoj ima formulu IV:
filtering the immunoglobulin solution through a combination of a first and second filter, whereby the first filter comprises a pre-filter with a pore size of 3.0 µm and a main-filter with a pore size of 0.8 µm and the second filter comprises a pre-filter with a pore size of 0.45 µm and a main-filter with a pore size of 0.22 µm, and thereby preparing an immunoglobulin solution. 
nanošenje otopine imunoglobulina na kombinaciju prve i druge filterske jedinice, pri čemu prva filterska jedinica sadrži predfilter s veličinom pora od 3,0 um i glavni filter s veličinom pora od 0,8 um, a druga filterska jedinica sadrži predfilter s veličinom pora od 0,45 um i glavni filter s veličinom pora od 0,22 um, s tlakom od 0,1 do 4,0 bara, te se time proizvodi otopina imunoglobulina.
Composition comprising shellac and/or a salt thereof and sodium starch glycolate and at least one physiologically acceptable excipient, characterised in that it is a coating composition. 
HR P20151125 T1 PATENTNI ZAHTJEVI Pripravak koji sadrži šelak i/ili njegovu sol, natrijev škrobni glikolat i najmanje jednu fiziološki prihvatljivu pomoćnu tvar, naznačen time što je pripravak za oblaganje.
generating a relay message (S2) which comprises said first phase relation information (M1) and transmitting from said relay location said relay message (S2) via said power line (R, S, T, N) or via optical cable or via radio communication channels. 
- stvaranje relejne poruke (S2) koja sadrži spomenutu informaciju prvog faznog odnosa (MI) i - odašiljanje spomenute relejne poruke (S2) od spomenute relejne lokacije putem spomenute energetske linije (R, S, T, N) ili putem optičkog kabla ili putem radio komunikacijskih kanala. t>& to m» KP)
in which is halogen, preferably fluorine or chlorine, 
R! je halogen, poželjno fluor ili klor, R- je vodik i R? je hidroksil ili 20
Described are compositions, containing a. compounds selected from (i.) hydrogenated and/or non-hydrogenated, ethoxylated and/or propoxylated triglycerides of ricinoleic acid having degree of ethoxylation and/or propoxylation of ≧20, (ii.) addition products of 2-50 mol ethylene oxide on sorbitan monoesters and/or diesters of saturated or unsaturated fatty acids having 6-22 carbon atoms, and (iii.) addition products of 2-50 mol ethylene oxide and 1-20 mol propylene oxide on alpha olefin epoxides having 8-22 carbon atoms and ring-opened with polyols, b. ethoxylated and/or propoxylated glycerol fatty acid monoester and/or diester having degree of ethoxylation of <20, c. polyol selected from glycerol, diglycerol, trigylcerol, tetraglycerol, alkylene glycols and polyalkylene glycols, d. glycerol fatty acid monoester of general formula (I), where R1 is saturated or unsaturated, branched or linear group having 9-19 carbon atoms, and e. ≦20 wt % water. 
HR P20181116 T1 HR P20181116 T1 PATENTNI ZAHTJEVI 1. = Sastav koji sadrži a. b. barem jedan spoj izabran iz skupine koja se sastoji od (a-1) - hidrogenirani i/ili nehidrogenirani, etoksilirani 1/ili propiksilirani trigliceridi ricinoleične kiseline sa stupnjem etoksilacije i/ili stupnjem propoksilacije većim ili jednakim 20, posebno od 20 do 60, (a-2) = adicijski produkti od 2 do 50 mol etilen oksida na sorbitan mono- i/ili diestere zasićenih ili nezasićenih masnih kiselina koje imaju 6 do 22 atoma ugljika, te (a-3) - adicijski produkti od 2 do 50 mol etilen oksida i 1 do 20 mol propilen oksida na alfa-olefin epokside koji imaju 8 do 22 atoma ugljika i prsten-otvoren poliolima, barem jedan etoksilirani i/ili propoksilirani mono- i/ili diester glicerol masne kiseline sa stupnjem etoksilacije od manje od 20, poželjno 3 do 19, posebno 3 do 15,
cooling fan adapted to flow air on said cooling element shaped conduit. The device of clause 5 further comprising a safety pressure outlet to relief pressure from said chamber when said pressure exceeds predefined pressure level; 
Sustav prema zahtjevu 1, naznačen time, da nadalje sadrži sigurnosni izlazni tlak (20D) za oslobađanje tlaka iz navedene komore kada navedeni tlak prelazi unaprijed definiranu razinu tlaka.
the disease or condition is a hematologic malignancy selected from the group consisting of lymphoma, multiple myeloma, and leukemia; 
Spoj ili pripravak za uporabu sukladno patentnom zahtjevu 7, naznačeno time što bolest ili stanje je odabrano iz skupine sastavljene od:
A compound that binds to and activates the erythropoietin receptor (EPO-R), which compound comprises a peptide dimer having the formula: wherein 
Spoj koji se veže na i aktivira eritropoctinski receptor (EPO-R), gdje navedeni spoj sadrži peptidni dimer formule:
The method of claim 3 wherein said skin disorder is atopic dermatitis or psoriasis. 
Spoj za uporabu prema zahtjevu 6, naznačen time da je navedeni kožni poremećaj atopijski dermatitis ili psorijaza.
or an isolated mutant of a wild-type staphylococcal leukocidin subunit polypeptide comprising SEQ ID NO: 16, 17, 21, 22, 23, 24, 25 or 26, wherein the mutant staphylococcal leukocidin subunit polypeptide comprises an amino acid substitution at a position corresponding to K102 of SEQ ID NO: 17, which reduces toxicity of the mutant leukocidin subunit relative to the corresponding wild-type leukocidin subunit. 
ili izolirani mutant polipeptida divljeg tipa stafilokokne podjedinice leukocidina koji sadrži SEQ ID NO: 16, 17, 21, 22, 23, 24, 25 ili 26, pri čemu mutant stafilokokne podjedinice leukocidina sadrži aminokiselinsku supstituciju na položaju koji odgovara K102 u SEQ ID NO: 17, što smanjuje toksičnost mutanta podjedinice leukocidina u odnosu na odgovarajuću podjedinicu divljeg tipa leukocidina.
The antibody according to the use of claim 17, wherein said B-cell disorder is a B-cell lymphoma. 
Protutijelo prema zahtjevu 19, naznačeno time, da spomenuti poremećaj B-stanice je limfom B-stanice.
According to an embodiment, the organogelator (VII) comprises at least 2 organogelling molecules of different chemical structure, all of the three units A, D and C being found in the organogelator. 
Mješavina u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačena time što organogelator (VII) sadrži najmanje 2 organoželirajuće molekule različite kemijske strukture, gdje se u organogelatoru nalaze sve tri jedinice A,DiC.
A composition according to any one of claims 1 to 3, wherein the effective temperature is approximately equal to or less than about 5°C. 
Sastav prema bilo kojem od zahtjeva 1 do 3, gdje je količina proizvoda razgradnje H168/79 približno jednaka ili manja od oko1.0%.
Percentage inhibition is calculated from fractional responses elicited by test compound and vehicle. 
Postotak inhibicije je izračunat iz frakcijskih odgovora dobivenih sa testiranim spojem ili prijenosnikom.
An isolated peptide of less than 15 amino acids having cytotoxic T cell inducibility, wherein said peptide is selected from the group consisting of peptides comprising the amino acid sequence of SEQ ID NO: 30, 19, 22, 34, or 358. 
Peptid od manje od 15 aminokiselina koji može inducirati citotoksičnu T-stanicu, naznačen time što navedeni peptid ima aminokiselinski slijed SEQ ID NO:376 ili 379.
A compound of any one of claims 1 to 3 in free base or pharmaceutically acceptable acid addition salt form, for use in the treatment or prevention of a disease or condition in which a7 nAChR activation plays a role or is implicated. 
Farmaceutski sastav, naznačen time, da sadrži spoj prema bilo kojem zahtjevu 1 do 10, u slobodnom bazičnom obliku ili u obliku farmaceutski prihvatljive dodatne kiselinske soli, s pripojenim farmaceutskim nosačem ili razrjeđivačem.
The product of claim 1 wherein said process further comprises removing P1 from the Har residue of a compound of formula I: wherein P1 is an amino protecting group, thereby forming the compound of formula II. 
Mpa-OR PHar-Gir-AsO-P,+Trm-Pro-Cys-NH, nn -a-_> u čemu je P, amino zaštitna skupina, da na taj način nastane spoj formule II.
The leveling spacer according to the preceding claims, characterized in that said knob (15) can be made monolithically of plastic material. 
Umetak za niveliranje prema prethodnim zahtjevima, naznačen time, da navedeni čvor (15) može biti izrađen monolitno od plastičnog materijala.
Inactivation of living cells may also be performed, as may centrifugation. 
Inaktivacija živućih stanica se također može izvesti, kao i centrifugiranje.
The present invention relates to the method of manufacturing of 7-ethyl-10-hydroxycamptothecin of formula I which is characterized in that 7-ethyl-1,2,6,7-tetrahydrocamptothecin of formula IV is oxidized with an oxidizing agent selected from the group comprising iodosobenzene, an ester of iodosobenzene, sodium periodate, potassium periodate, potassium peroxodisulfate and ammonium peroxodisulfate, in the presence of a solvent formed by a saturated aliphatic monocarboxylic acid comprising 1 to 3 carbon atoms, and in the presence of water. 
Ovaj izum odnosi se na postupak dobivanja 7-etil-10-hidroksikamptotecina formule I (MV) se oksidira oksidansom, kojeg se bira iz skupine koju čine jodozobenzen, ester jodozobenzena, natrijev perjodat, kalijev perjodat, kalijev peroksodisulfat i amonijev peroksodisulfat, u prisutnosti otapala, kojeg čine zasićena alifatska monokarboksilna kiselina s 1 do 3 atoma ugljika, u prisutnosti vode.
separation of predetermined phases or substances from the rest of the extracted fluid; 
odvajanja zadanih faza ili tvari od ostatka ekstrahiranog fluida;
A composition for use in treating Pompe disease, wherein the composition comprises a rAAV2/9 vector, wherein the rAAV2/9 vector comprises a heterologous nucleic acid molecule encoding acid a-glucosidase, wherein the heterologous nucleic acid is operably linked to a desmin promoter, a myocyte specific enhancer factor 2 enhancer element, and a MyoD enhancer element, wherein the composition is administered to a subject in need thereof via intramuscular, intrathoracic, intraspinal, intrathecal, intracisternal, or intravenous injection. 
Sastav za upotrebu u liječenju Pompeove bolesti, koja se sastoji od vektora rAAV2/8, pri čemu rAAV2/8 vektor sadrži heterolognu molekulu nukleinske kiseline koja kodira kiselu a-glukozidazu, pri čemu je heterologna nukleinska kiselina operativno povezana s promotorom gena za dezmin, pojačivačkim elementom pojačivačkog faktora 2 specifičnim za miocit i MyoD pojačivačkim elementom, pri čemu se sastav daje subjektu kome je to potrebno intramuskularnom, intratorakalnom, intraspinalnom, intratekalnom, intracisternalnom ili intravenskom injekcijom.
A compound of Formula (I) according to any one of the preceding claims wherein the ring A is selected from the group consisting of wherein R6 is hydrogen, halogen, benzyloxy or phenoxy, phenyl, pyrazole, C3-C6 cycloalkyl, optionally substituted with halogen, preferably substituted with fluoro. 
dr Sa NK i i gdje R5 jest vodik, halogen, benziloksi ili fenoksi, fenil, pirazol, Cs-C4 cikloalkil, koji može biti supstituiran halogenom, preferirano supstituiran fluorom.
Rx and Ry are independently selected from hydrogen, alkoxycarbonyl, alkyl, alkylcarbonyl, unsubstituted aryl, unsubstituted arylalkoxycarbonyl, unsubstituted arylalkyl, unsubstituted cycloalkyl, unsubstituted heterocyclyl, and (NRx'Ry')carbonyl, wherein Rx' and Ry' are independently selected from hydrogen and alkyl. 
Rx i Ry su nezavisno izabrani između vodika, alkoksikarbonil, alkil, alkilkarbonil, nesupstituirani aril, nesupstituirani arilalkoksikarbonil, nesupstituirani arilalkil, nesupstituirani cikloalkil, nesupstituirani heterociklil, i (NRxRy)karbonil, gdje su Rx' i Ry' nezavisno izabrani između vodika i alkila.
at least one stringer element (31) interposed between said lateral upright elements (21, 22) and arranged, when the parapet (1) is assembled onto the scaffolding, substantially parallel to the trampling floor; and 
- < najmanje jedan element za pojačanje (31) postavljen je između navedenih bočnih okomitih elemenata (21, 22) 1 izvedena tako da kada je zaštitna ograda (1) postavljena na skelu, on je u osnovi paralelan na gazište skele
A method for producing a fermentation product, which method comprises producing a fermentable sugar by contacting lignocellulosic material with a polypeptide according to claim 1 and/or a composition according to claim 9, and fermenting the resulting fermentable sugar to produce a fermentation product. 
Postupak za proizvodnju fermentacijskog produkta, naznačen time da postupak obuhvaća proizvodnju fermentabilnog šećera dovođenjem u kontakt lignoceluloznog materijala s polipeptidom prema zahtjevu 1 i/ili pripravkom prema zahtjevu 9, te fermentiranje nastalog fermentirajućeg šećera da se dobije fermentacijski produkt.
1: embodiment of the system of the invention 
Datum objave europske prijave patenta:
In the case the salt are administered rectally their content in a suppository or microenema accounts for 0.5 to 40% by weight. 
U slučaju da se sol daje rektalno, njezin sadržaj u čepiću ili mikroenemi iznosi 0,5 do 40 mas. %.
The composition of claim 7, wherein the adjuvant is selected from the group consisting of an oil-in-water adjuvant, a polymer and water adjuvant, a water-in-oil adjuvant, an aluminum hydroxide adjuvant, a vitamin E adjuvant and combinations thereof. 
Pripravak u skladu s patentnim zahtjevom 7, naznačen time što adjuvans se bira iz skupine koju čine adjuvans tipa ulja u vodi, polimer i voda kao adjuvansi, adjuvans tipa voda u ulju, aluminijev hidroksid kao adjuvans, vitamin E kao adjuvans i njihove kombinacije.
This sequence (i) lacks the N-terminus methionine of SEQ ID NO: 3, (ii) lacks the alanine residue found at the N-terminus of natural mature human IL-2 as seen in SEQ ID NO: 4, and (iii) has a serine substitution at the Cys-125 residue seen in SEQ ID NO: 4. 
Ovoj sekvenci (1) manjka N-teminalni metionin od SEQ ID NO:3, (ii) manjka alaninski ostatak koji se nalazi na N-terminusu prirodnog zrelog ljudskog IL-2, kako se vidi u SEQ ID NC: 4, i (iii) ima serinsku supstituciju na Cys-125 ostatku koja se vidi u SEQ ID NO: 4.
The daily dose can be divided, especially when relatively large amounts are administered as deemed appropriate, into several, for example 2, 3 or 4, part administrations. 
Dnevna doza može biti podijeljena, posebno kad se primjenjuju relativno velike količine kao odgovarajuće, u nekoliko, na primjer, 2, 3 ili 4 primjene.